Halozyme: ENHANZE Drug Delivery Technology Part Of Argenx's Positive Trial Of SC Efgartigimod In GMG
22/3 08:01
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) announced Tuesday that its proprietary ENHANZE drug-delivery technology has been used in argenx's (ARGX) Phase 3 ADAPT-SC study of subcutaneous or SC efgartigimod (1000mg efgartigimod-PH20) to treat generalized myasthenia gravis or g...